PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
about
The HIV glycan shield as a target for broadly neutralizing antibodiesA Blueprint for HIV Vaccine DiscoveryHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designMolecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization BreadthBroadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding GlycansAntibody potency relates to the ability to recognize the closed, pre-fusion form of HIV EnvHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesRecent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Passive immunization against HIV/AIDS by antibody gene transfer.Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120Clonify: unseeded antibody lineage assignment from next-generation sequencing dataProbing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesPlasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational methodHIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal AntibodiesImmunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.CATNAP: a tool to compile, analyze and tally neutralizing antibody panelsN463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.CD4 binding determinant mimicry for HIV vaccine design.Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodiesProteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibilityHIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variantsNeutralizing antibodies to HIV-1 induced by immunization.Role of IL-21 and IL-21 receptor on B cells in HIV infection.Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgGCD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.
P2860
Q26786540-6A683767-6D85-4454-B2C0-3B55B4869BFFQ26829865-F22646DB-1A80-4BD9-AD08-A2AC91C78042Q27022055-23F2DD45-E91F-4C83-9C34-6C232AC16328Q27322403-65BC8C47-C343-4483-8959-14D4BA7D510FQ27676728-935B363D-9D95-423A-AAA7-CF6A218C1313Q27678062-A1591E21-600E-425E-9E8C-CDD89302282AQ28256508-7FB1B3BA-F44E-47E0-9224-E522FFB3A331Q28602877-3C0BB6ED-CD64-42C1-A087-D615D3C631E8Q30353580-594A03E3-8DF0-40EF-89DE-77B61761449EQ30358434-9E1B015E-095E-4DFD-8A32-54461784C553Q30524225-9F7E84A0-E80C-48E3-9C60-913A5DD55166Q31082802-BC7F43FF-F2B1-46DE-AC93-573D4E1AFE75Q33821896-7C398DAA-803F-4224-A46C-225097FD2101Q34172295-AB02D9B0-F8A7-4B33-808E-A07040D320F6Q34177732-D0D5429F-3B86-4C43-96F2-49A9DFF8AE69Q34374835-699BFBBF-70B3-4BF0-8005-6CE8F8A1E62BQ34478071-62BB43B2-BB45-4B16-B459-1149A3F86A5DQ34550046-B7B5012B-2F9A-4BD2-9FDD-0CE5CB5D88E6Q34593860-37F7C851-E4A9-4DB2-BEB2-C55D3C7DD23FQ34594905-6D22DB51-5DA6-4D7A-8F4F-97A77D8D6CC5Q34851484-A72EC83B-5AF2-41F2-B2E2-3DC99E1A022EQ35124761-2EDD66B7-188B-48F2-9238-41C00218DFABQ35640998-B7EE189D-420B-43D5-812C-0362B4FE09B9Q35743897-18942C4C-0A2B-4203-AF68-170E6A24B048Q35745442-A4E6A7C5-81C6-437F-B79D-16EBB6D3B256Q35810109-B61457BB-9C39-40EA-BB1C-64F37F337E0CQ35864051-F6CADC62-241E-47F8-8874-3417BC730797Q36086357-D96EBA75-FF11-4D70-A931-4CF745AFEFA7Q36248197-FC77F509-E2FD-4FF7-82F5-28C8E32BF687Q36364955-D3BFF4D0-AEE0-4387-8704-97B8C3CF8C7BQ36466846-084852CF-D944-45E8-88C2-692533F60CC7Q36469664-93771694-1458-49C8-8C68-06252981E3BFQ36531018-792B3713-DC8A-490E-AA02-224DB1C1BFB3Q36559735-B94BCB72-D6B7-4631-8ED0-DB151BEBF5CDQ36583109-F1C3A20F-24A5-4E12-AFFB-A437BDB3C45BQ36588632-4C43A388-E961-4409-A98F-438BD3C57412Q36603515-48557462-E226-440A-8704-0BE5ED9A85D4Q36670538-697C1C94-6BB4-4882-B381-F8108DD8259EQ36759899-276A2474-F3D0-4B87-86FD-0C8C68F466E2Q36810796-3F124A68-0F52-4352-A7BB-01D4C7C93043
P2860
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@ast
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@en
type
label
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@ast
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@en
prefLabel
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@ast
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@en
P2093
P2860
P356
P1433
P1476
PGV04, an HIV-1 gp120 CD4 bind ...... changes characteristic of CD4.
@en
P2093
Alejandra Ramos
Dennis R Burton
Emilia Falkowska
Laura M Walker
Michael S Seaman
Peter D Kwong
Richard T Wyatt
Stephanie Moquin
Terri Wrin
Tongqing Zhou
P2860
P304
P356
10.1128/JVI.06973-11
P407
P577
2012-02-15T00:00:00Z